Bottom line
SMAP vs FSSNX: the short answer
SMAP (Amplify Small-Mid Cap Equity ETF) and FSSNX (Fidelity Small Cap Index Fund) are both etfs.
FSSNX is cheaper at 0.025% vs 0.6% — a difference of $58 a year per $10,000 invested.
Over one year, FSSNX returned +12.9% vs +3.7% for SMAP (reporting dates differ).
Updated Nov 19, 2026
SMAP vs FSSNX side by side
| SMAP | FSSNX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | Amplify | Fidelity |
| Category | Small-Cap | Small-Cap |
| Expense ratio | 0.6% | 0.025% |
| Annual cost per $10k | $60 | $2.5 |
| 10-yr cost on $10k (prospectus) | $750 | $32 |
| Max front load | None | — |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +3.7% | +12.9% |
| 5-yr return (annualized) | — | +6.2% |
| 10-yr return (annualized) | — | +9.8% |
| Best quarter | +5.2% | +31.3% |
| Worst quarter | −3.3% | −30.6% |
| Net assets (fund) | — | $34.1B |
| Number of holdings | — | 1,966 |
| Portfolio turnover | 4% | 2% |
| Returns as of | Dec 31, 2024 | Jun 30, 2026 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | SMAP | FSSNX | Difference |
|---|---|---|---|
| 2025 | +3.7% | +12.9% | −9.3% |
Source: Fund prospectus bar charts
Holdings overlap
SMAP and FSSNX share none of their top holdings.
SMAP top 10
FSSNX top 10
- Fidelity Revere Street Trust — 8.41%
- Fidelity Revere Street Trust — 0.41%
- Moog Inc — 0.36%
- Hut 8 Corp — 0.36%
- Umb Financial Corp — 0.35%
- Cytokinetics Inc — 0.33%
- Viasat Inc — 0.31%
- Brightspring Health Services Inc — 0.31%
- Glaukos Corp — 0.31%
- Caretrust REIT Inc — 0.31%
FAQ
What is the difference between SMAP and FSSNX?
SMAP (Amplify Small-Mid Cap Equity ETF) and FSSNX (Fidelity Small Cap Index Fund) are both etfs. FSSNX is cheaper at 0.025% vs 0.6% — a difference of $58 a year per $10,000 invested.
Which is cheaper, SMAP or FSSNX?
FSSNX has the lower expense ratio (0.025%).
Should I own both SMAP and FSSNX?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.